Having determined the molecular mechanism by which recombinant IFNβ treatment results in enhanced CD38 expression on AML cells, we next asked whether pDC-dependent IFNβ production after R848 treatment could enhance CD38 expression on AML cells in a paracrine fashion. This evidence concerns the gene PDC and acute myeloid leukemia.